Video

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Related Videos
Related Content
CAR T cell therapy in leukemia -- Image credit: LASZLO | stock.adobe.com
April 23rd 2025

Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment

Amir Ali, PharmD, BCOP Tammy Harutunyan, PharmD Candidate Arman Melikyan, PharmD Candidate
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
3D rendering of thrombosis in an artery | Image Credit: © Matthieu - stock.adobe.com
April 22nd 2025

Thrombosis May Increase Risk of Cardiovascular Disease, Secondary Cancers in Myeloproliferative Neoplasms

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Red blood cells | Image Credit: © digitalpochi - stock.adobe.com
April 18th 2025

Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients

Alexandra Gerlach, Associate Editor
Cancer cells in the blood stream | Image Credit: © freshidea - stock.adobe.com
April 17th 2025

Zanubrutinib Plus Venetoclax and Obinutuzumab Yields Deep Remissions in Patients With Chronic Lymphocytic Leukemia

Alexandra Gerlach, Associate Editor